Mehra is a seasoned financial executive with decades of financial knowledge across biotech and global healthcare.
TheRas, Inc. d/b/a BBOT, a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, appointed Uneek Mehra as Chief Financial Officer. Mehra brings over 28 years of global financial and business leadership experience across the biotechnology and pharmaceutical industries.

Mehra most recently served as Chief Financial & Business Officer at 4D Molecular Therapeutics (4DMT), where he led financing rounds and capital allocation efforts to ensure funding for two large Phase 3 programs. 

Before that, he was the Chief Financial and Business Officer at Myovant Sciences Ltd., a public biopharma company, where he built partnerships and enabled commercial growth for its Oncology and Women’s Health products. He also led Myovant Sciences’ acquisition by Sumitomo Pharma. 

His earlier leadership roles include Chief Financial Officer at PACT Pharma and Proteus Digital Health, as well as 13 years at Novartis, where he led strategic capital allocation and drove commercial financial performance for multi-billion-dollar businesses. He began his career in senior finance roles at IBM and Citibank before moving into healthcare.

"We are thrilled to welcome Uneek to BBOT," said Eli Wallace, PhD, Chief Executive Officer of BBOT. "His proven track record of driving financial strategy, building high-impact partnerships, and supporting the growth of innovative biotech companies will be instrumental as we continue to advance our promising oncology pipeline, and scale our operations."

BBOT Appoints Uneek Mehra as Chief Financial Officer

BBOT, a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, has appointed Uneek Mehra as Chief Financial Officer. Mehra, a seasoned financial executive with over 28 years of experience in biotech and healthcare, previously held leadership roles at companies like 4DMT, Myovant Sciences, and Novartis.